Navigation Links
Novartis MS Drug Shows Promising Results

Data from the extension of a Phase II study to 12 months confirm the significant effects of FTY720, a novel oral medication//, for the treatment of patients with relapsing multiple sclerosis (MS).

The data, presented at the ECTRIMS/ACTRIMS meeting in Thessalonica, Greece, showed that both patient groups taking FTY720 (1.25 mg and 5 mg) who had experienced a reduction in their annualized relapse rate of more than 50% during the first six months of the study compared to placebo maintained this low relapse rate during the subsequent six-month extension.

In patients who switched from placebo to either the 1.25 mg or 5 mg dosing of FTY720 after six months, the annualized relapse rate was reduced by at least 70% during the second six-month study phase compared to the first six months on placebo.

More than 80% of patients who received FTY720 for up to 12 months were free from lesions showing active inflammation on magnetic resonance imaging (MRI) at month twelve irrespective of their FTY720 treatment dose (1.25 mg or 5 mg).

"We are excited by these full-year study results confirming the significant effect of oral FTY720 on reducing both clinical relapses and inflammatory disease activity that we first saw during the six-month placebo-controlled phase of the study," said chief investigator Professor Ludwig Kappos, MD, Department of Neurology at the University Hospital in Basel, Switzerland, "We hope that the magnitude of benefits shown in Phase II will be confirmed in the larger scale Phase III study program expected to be launched soon." Based on the positive Phase II study results, Novartis is in discussions with regulatory authorities about the FTY720 Phase III program, which is expected to be launched by the end of 2005.

Over two million people worldwide are estimated to suffer from multiple sclerosis, which is the leading cause of neurological disability in young adults. MS is the most common chronic, disabling di
'"/>




Page: 1 2 3

Related medicine news :

1. Novartis files application with FDA for Zometa
2. Canine Painkiller unveiled by Novartis
3. Glivec the hot cancer drug from Novartis
4. Zometa [Novartis Drug] For Treatment Of Paget’s Diseas
5. Bird-flu Vaccine Adjuvant Contract Goes to Novartis
6. Drop Patent Petition, Activists Ask Novartis
7. E.U. Panel Backs Novartis Mock-up Pandemic Flu Vaccine
8. Indian Court Refers Novartis Plea for Patent on Anti-cancer Drug to a Separate Board
9. Novartis Gleevec Found Effective in Treating Gastro-intestinal Tumors
10. Novartis Drug Diovan Shows Superior Benefits
11. Experimental treatment for Ebola Virus Shows promising results in mice
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Novartis Drug Shows Promising Results

(Date:10/31/2014)... for low back pain caused by spinal stenosis varies ... a new report says. "Nearly 80 percent of ... in their lives, and about 30 million people a ... co-author Brook Martin, of the Dartmouth Institute of Health ... release. In spinal stenosis, thickening of tissue surrounding ...
(Date:10/31/2014)... IL – New research suggests that insomnia is a ... and other unintentional fatal injuries. The results underscore the ... the National Healthy Sleep Awareness Project. , Results show ... a dose-dependent manner with the number of insomnia symptoms ... 2.8 times more likely to die from a fatal ...
(Date:10/31/2014)... The Suspension Revolution review published by Daily Gossip ... Dan Long, a suspension training specialist. , Long ... life coach. The author of this program claims that ... impossible , The Suspension Revolution review reveals that this ... efficiency when it comes to burning fat, building muscles, ...
(Date:10/31/2014)... Florida Air Academy, the Melbourne ... grades 6-12, is taking the lead when it ... concussions, becoming the first high school in central ... Assessment and Cognitive Testing) computerized assessment to all ... grabs the headlines, and the Centers for Disease ...
(Date:10/31/2014)... Phoenix dentist , Dr. Christy, is ... Whether patients simply need routine care or have a more ... now to get that necessary care. The right dental treatments ... and even essential treatments due to financial concerns. Throughout the ... any treatments offered by the team at Christy Dental Care. ...
Breaking Medicine News(10 mins):Health News:Spinal Surgery Varies by Region in U.S.: Study 2Health News:Insomnia increases risk of motor vehicle deaths, other fatal injuries 2Health News:Suspension Revolution Review Reveals Dan Long's New Suspension Workout Plan 2Health News:Florida Air Academy Tackling Concussions Head-On 2Health News:Florida Air Academy Tackling Concussions Head-On 3Health News:Phoenix Dentist, Dr. Christy, is Now Offering Ten Percent Off On All Dental Treatments for the Month of November 2
... has a significant association with feelings of external pressure ... girls, especially those who are white, suggests a research ... Minneapolis, Minn., at SLEEP 2011, the 25th Anniversary Meeting ... Results show that pressures to have a thin body ...
... cutting-edge research that promises to revolutionise the diagnosis and treatment ... used in the long-term to develop a radical new type ... dummy to meet the different needs of individual patients. If ... market within 4 years. The research is being ...
... breakthrough by researchers at the Institut de recherches cliniques de ... a scientific journal of the Cell Press group. Led ... new requirement for the proper functioning of the Sonic Hedgehog ... proteins that gives cells the information needed for the embryo ...
... Gordon HealthDay Reporter , MONDAY, June 13 (HealthDay News) ... the park may depend on the time of the game, and ... night owl. New research on Major League Baseball players suggests ... game starts before 2 p.m., while night owls are at their ...
... Western Reserve University School of Medicine have discovered a ... to chronic health problems. If they learn to ... macrophages, "We have a shot at a novel treatment ... disease and cancer," said Mukesh K. Jain, MD, Ellery ...
... A new study published by the American Physiological Society ... 2 diabetes can begin in the womb, giving new ... disease at the center of a worldwide epidemic. The ... are even moderately undernourished while pregnant and breastfeeding, their ...
Cached Medicine News:Health News:White adolescent girls may be losing sleep from the pressure to be thin 2Health News:New software 'hearing dummies' pave the way for tailor-made hearing aids 2Health News:New software 'hearing dummies' pave the way for tailor-made hearing aids 3Health News:A scientific breakthrough at the IRCM could help understand certain cancers 2Health News:Hey, Batter: Your Sleep Habit May Affect Your Swing 2Health News:Hey, Batter: Your Sleep Habit May Affect Your Swing 3Health News:Genetic factor controls health-harming inflammation in obese 2Health News:Undernourishment in pregnant, lactating females found key to next generation's disease 2Health News:Undernourishment in pregnant, lactating females found key to next generation's disease 3
(Date:10/31/2014)... October 31, 2014 Today, Analysts ... CELG ), Bristol-Myers Squibb Co. (NYSE: ... UNH ), Sanofi SA (NYSE: SNY ) ... these notes ahead of publication. To reserve complementary membership, ... ,-- ,Celgene Corporation Research Reports ,On October 23, 2014, ...
(Date:10/31/2014)... 2014 British Journal of ... to discuss "male orgasmic dysfunction" with their doctor prior ... prostate symptoms while preserving sexual function   ... of a paper in the British Journal of Urology ... to discuss with their doctors the likely impact of ...
(Date:10/31/2014)... -- Migranade, Inc. announced today the new migraine medication, ... million U.S. migraine sufferers November, 2014. The medicine is ... cause of migraines and not just the symptoms. While ... Migranade is assured to be a game changer in ... at http://www.migranade.com and will soon hit the ...
Breaking Medicine Technology:Financial Results, Acquisition Agreement, and Legal Issue Update - Research Reports on Celgene, Bristol-Myers, UnitedHealth, Sanofi and Actavis 2Financial Results, Acquisition Agreement, and Legal Issue Update - Research Reports on Celgene, Bristol-Myers, UnitedHealth, Sanofi and Actavis 3Financial Results, Acquisition Agreement, and Legal Issue Update - Research Reports on Celgene, Bristol-Myers, UnitedHealth, Sanofi and Actavis 4Financial Results, Acquisition Agreement, and Legal Issue Update - Research Reports on Celgene, Bristol-Myers, UnitedHealth, Sanofi and Actavis 5Financial Results, Acquisition Agreement, and Legal Issue Update - Research Reports on Celgene, Bristol-Myers, UnitedHealth, Sanofi and Actavis 6Sexual Dysfunction No Longer Inevitable When Treating Enlarged Prostate 2Game Changing Migraine Medication To Be Available November 2014 2
... Omnicell, Inc . (NASDAQ: OMCL ... solutions and analytics software for healthcare facilities, today announced ... medication automation products for clinical use in China. ... Chinese hospitals to access advances in operational improvements similar ...
... N.J., Nov. 28, 2011  Johnson & Johnson (NYSE: JNJ ... Health Care Conference on Tuesday, Nov. 29 th at The ... Ethicon will present in a session scheduled at 8:00 a.m. (Eastern ... and other interested parties by accessing the Johnson & Johnson website ...
Cached Medicine Technology:Omnicell Introduces Groundbreaking Mandarin-Language Medication Automation System for Use in Chinese Clinical Settings 2Omnicell Introduces Groundbreaking Mandarin-Language Medication Automation System for Use in Chinese Clinical Settings 3Omnicell Introduces Groundbreaking Mandarin-Language Medication Automation System for Use in Chinese Clinical Settings 4Omnicell Introduces Groundbreaking Mandarin-Language Medication Automation System for Use in Chinese Clinical Settings 5
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: